Genprex Enhances Leadership with Jose A. Moreno Toscano as New Chairman of the Board

Genprex, Inc., a pioneering clinical-stage gene therapy company, has announced a key addition to its leadership team with the appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors. This strategic move comes shortly after Ryan Confer was named President and CEO, as well as a Board member, signaling a season of executive enrichment for the Austin-based organization. The recent executive appointments underscore Genprex's commitment to advancing its mission of crafting innovative treatments for cancer and diabetes patients.

Steadfast Mission for Innovation and Growth

Jose A. Moreno Toscano brings to Genprex a wealth of experience from an illustrious career in various industry-leading companies. His expertise is expected to steer Genprex as it navigates the complex landscape of clinical research and development, particularly in the arenas of cancer and diabetes therapeutics. The Chairman's role is pivotal in providing governance and strategic direction, aiding the company in achieving its objectives of improving patient outcomes through cutting-edge gene therapies.

Charting a Future of Therapeutic Advancements

The biotechnology sector continues to be at the forefront of medical advancement, and companies like Genprex GNPX are central to this progress. Genprex's focus on gene therapy—an area of significant potential in medicine—positions the company to make substantial contributions to the fight against life-threatening diseases. With its headquarters nested in the scientific hub of Austin, Texas, Genprex stands on the frontier of health innovation, bolstered by a strengthened leadership team poised for guiding the company forward.

Genprex, Leadership, Appointment